IRRAS is a commercial stage, publicly-traded medical device company, that is dedicated to bringing needed innovation to the world of neurocritical care. IRRAS’ initial product, IRRAflow®, is the world’s first irrigating intracranial drainage system. Its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid, by using a dual-lumen catheter that combines active irrigation with controlled fluid drainage.
Additional, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels. IRRAS also has several other innovative neurocritical care products that are commercially available in the US, including the Hummingbird ICP monitoring system.